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Owing to the rapid and robust clinical effects, electroconvulsive therapy (ECT) represents an optimal model to develop and test treatment
predictors for major depressive disorders (MDDs), whereas imaging markers can be informative in identifying MDD patients who will
respond to a specific antidepressant treatment or not. Here we aim to predict post-ECT depressive rating changes and remission status
using pre-ECT gray matter (GM) in 38 MDD patients and validate in two independent data sets. Six GM regions including the right
hippocampus/parahippocampus, right orbitofrontal gyrus, right inferior temporal gyrus (ITG), left postcentral gyrus/precuneus, left
supplementary motor area, and left lingual gyrus were identified as predictors of ECT response, achieving accuracy of 89, 90 and 86% for
remission prediction in three independent, age-matched data sets, respectively. For MDD patients, GM density increases only in the left
supplementary motor cortex and left postcentral gyrus/precuneus after ECT. These results suggest that treatment-predictive and
treatment-responsive regions may be anatomically different but functionally related in the context of ECT response. To the best of our
knowledge, this is the first attempt to quantitatively identify and validate the ECT treatment biomarkers using multi-site GM data. We
address a major clinical challenge and provide potential opportunities for more effective and timely interventions for electroconvulsive
treatment.
Neuropsychopharmacology (2018) 43, 1078–1087; doi:10.1038/npp.2017.165; published online 23 August 2017

INTRODUCTION
Existing as the world’s primary cause of disability, major
depression is highly prevalent, affecting > 350 million lives
and contributing to ~ 1 million suicides each year (WHO).
The economic costs of depression outrank major health
conditions such as cancer and diabetes, and are estimated
near $200 billion in the United States alone (Mrazek et al,
2014). Although treatable, current interventions are only
moderately successful. Two-thirds of patients require two or
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more antidepressant drug trials and a third remain
unresponsive to multiple medication trials (McGrath et al,
2006). Electroconvulsive therapy (ECT) has an efficacy about
triple that of pharmacotherapy. ECT has several first-line
indications for depressive episodes including acute suicidality, catatonia, and psychosis (Weiner et al, 2001). In
contrast, treatment unresponsiveness to antidepressant
pharmacotherapy, a second-line indication for ECT presents
a more challenging clinical decision. Opting for another
antidepressant drug trial risks extending the depressive
episode in the context of non-response. However, due to
cost, potential side effects and stigma, ECT is typically used
only after numerous medication failures.
If the mental health clinician had an accurate prognostic
test of response, more personalized treatment algorithms
could improve clinical outcome. Such biomarkers could
inform both clinician and the individual patient about the
risks and benefits of an optimal treatment at a specific time
in the depressive episode. Past research has focused on

Predicting ECT outcomes with sMRI data
R Jiang et al

1079

clinical and demographic factors, but these biomarkers have
not achieved the accuracy required for translation
(Dombrovski et al, 2005; Haq et al, 2015). Some prior
neuroimaging studies have attempted to determine whether
treatment selection biomarkers (ie, assessing variations in
baseline brain measures) associate with ECT outcomes (Joshi
et al, 2016; Oudega et al, 2014; Ten Doesschate et al, 2014),
but most could be described more as post correlation rather
than prediction (Whelan and Garavan, 2014). Two key
factors motivate the current study. First, machine learning
and data mining techniques (eg, logistic regression and
support vector machines) provide a means for classifying
treatment outcome and identifying new prediction-related
networks. Second, ECT provides an optimal laboratory to
identify prediction and treatment response networks, due to
the magnitude and speed of response. Several recent ECTneuroimaging investigations have demonstrated the promise
of such methods for isolating prognostic biomarkers of ECT
response with accuracy between 78 and 89% (Redlich et al,
2016; van Waarde et al, 2015; Wade et al, 2016). However,
these investigations either used binary classification or lacked
validation with independent data sets. Identified brain areas,
which may serve as potential biomarkers, vary significantly
and sometimes remain contradictory because of the heterogeneity of depression or partially the differences in the
clinical characteristics of samples (Bora et al, 2012). Therefore, if biomarkers could be used to guide clinical practice,
they should be able to predict outcomes for new individuals
and independent cohorts based on the identified features
obtained from models developed previously with training
data (Wachinger et al, 2016). Furthermore, as reported by
American Psychiatric Association (2012), predictive biomarkers should have an accuracy greater than 80% to be
clinically useful.
In this study, we have three aims: (1) predict clinical
outcome of MDD after ECT (both depression rating changes
and remission status) with a data-driven individualized
prediction framework (Meng et al, 2017) by using pre-ECT
gray matter (GM) data; (2) verify the effectiveness of a set of
identified GM regions on ECT prediction by using
independent samples; and (3) assess the longitudinal changes
of these GM regions among MDD remitters, MDD nonremitters, and demographically matched healthy controls
(HCs). Based on above analyses, we expect to discover a set
of GM regions of interests (ROIs) that are able to better
predict individual clinical outcomes after ECT treatment
quantitatively for multi-site data, which is in accordance with
the Precision Medicine Initiative (Shah et al, 2016) released
by NIMH.

MATERIALS AND METHODS
Inclusion/Exclusion Criteria
Three data sets from existing ECT studies that followed
similar protocols were used, including University of New
Mexico (UNM; 38 MDD and 27 demographically matched
HCs), University of California at Los Angeles (UCLA; 42
MDD), and the Northwell Health-Long Island Jewish Health
System (LIJ; 17 MDD). All MDD patients were scanned
within 72 h of the first ECT treatment and after the ECT
series; HCs were scanned at two time points between 4- and

6-week intervals. The human research protections office at
each site approved the investigation and data-sharing
agreements. Inclusion criteria consisted of the following:
(1) diagnosis of MDD (with or without psychotic features);
(2) clinical indications for ECT; and (3) Hamilton Depression Rating Scale 24-item (HDRS-24) > 21 (Kellner et al,
2006); and (4) age range between 50 and 80 years for the
UNM sample. Exclusion criteria consisted of the following:
(1) defined neurological or neurodegenerative disorder (eg,
history of head injury with loss of consciousness > 5 min,
epilepsy, and Alzheimer’s disease); (2) other psychiatric
conditions (eg, schizophrenia, schizoaffective disorder, and
bipolar disorder); (3) current drug or alcohol-use disorder,
except for nicotine; and (4) contraindications to MRI.
Additional exclusion criteria for the HC group included
any current or past psychiatric history as confirmed by the
Structured Clinical Interview for DSM-IV-TR Disorders,
Research Version, Non-patient Edition (First et al, 2002).

Clinical Assessments
The primary clinical assessment was the HDRS before and
after the ECT sessions. UNM and LIJ used the HDRS-24 and
UCLA used the HDRS-17. ECT remission was defined as
> 50% reduction in HDRS and final HDRS-24 score ⩽ 10
(UNM, LIJ) or HDRS-17 ⩽ 7 (UCLA) (Heijnen et al, 2010). In
UNM site, all MDD patients continued with antidepressant
and antipsychotic medications with minimal medication
changes during the ECT series (dose-titration only). UCLA
and LIJ both discontinued antidepressant medications before
and during the ECT series, whereas some LIJ subjects received
lorazepam as needed for anxiety during the ECT series.

Demographics and Clinical Outcomes
For the UNM site, 38 subjects with MDD (age 63.8 ± 9.0 years,
24 males) and 27 HCs (age 60.0 ± 8.3 years, 11 males)
completed the study (Table 1). MDD subjects had both
psychotic (n = 16) and non-psychotic (n = 22) depressive
episodes. Most UNM MDD subjects (36/38, 95%) were
treated with antidepressant and concurrent antipsychotic
(21/38, 55%) medications. Antidepressant medications included select serotonin reuptake inhibitors (n = 15), serotonin
norepinephrine reuptake inhibitors (n = 16), norepinephrine
dopamine reuptake inhibitors (n = 1), and tricyclic antidepressants (n = 4). MDD subjects received an average of
11.1 ± 3.2 ECT treatments with both right unilateral (n = 30)
and bitemporal (n = 8) electrode placements. UNM MDD
subjects improved from a baseline (pre-ECT) HDRS-24 of
32.8 ± 7.5 to a post-ECT HDRS-24 of 8.6 ± 9.6 (T(37) = 11.8,
po0.01, 71.1% remitters). The majority of UNM subjects
received longitudinal neuropsychological screening with the
Repeatable Battery of Neuropsychological Status (Randolph
et al, 1998), which demonstrated a modest improvement in
total score (scaled score mean of 100 ± 15, pre-ECT:
84.9 ± 19.8, post-ECT: 89.2 ± 20.0, T(29) = 2.0, p = 0.06).
Among all five subscales, only the immediate memory demonstrated a significant improvement (pre-ECT: 79.1 ± 21.4,
post-ECT: 89.9 ± 19.6, T(29) = 4.3, p = 1.8e-4) in patients, see
Supplementary Table S2.
The validation data sets include a wider age range from 20
to 74 years. UCLA included 42 MDD subjects (age 42.8 ± 14.1
Neuropsychopharmacology
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Table 1 Clinical and Demographic Information
UNM-MDD mean (SD)
Sample size (n)
Age: years

UCLA-MDD mean (SD)

38
63.8 (9.0)

LIJ-MDD mean (SD)

10

7

27

57.6 (7.8)

62.0 (7.5)

60.0 (8.3)

5/2

11/16

Gender: M/F

24/14

Total number of ECT treatments

11.1 (3.2)

10.7 (3.6)

Pre-ECT HDRSa

32.8 (7.5)

25.5 (4.0)

30.7 (4.8)

Post-ECT HDRSa

8.6 (9.6)

10.8 (6.8)

16.7 (11.8)

24.1 (12.6)

14.7 (7.7)

14.0 (11.4)

ΔHDRS (pre–post)

UNM-HC mean (SD)

5/5

7.3 (3.5)

Responder (%)

30/38 (78.9)

2/10 (20)

4/7 (57.1)

Remitter (%)

27/38 (71.1)

2/10 (20)

3/7 (42.9)

Abbreviations: ECT, electroconvulsive therapy; HDRS, Hamilton Depression Rating Scale; LIJ, Long Island Jewish Health System; UCLA, University of California at Los
Angeles; UNM, University of New Mexico.
a
UNM and LIJ used HDRS-24, UCLA used HDRS-17.

years, 18 males) and LIJ included 17 MDD subjects
(age 47.2 ± 15.1 years, 10 males). For the age-matched subjects
with UNM (ie, age > 50 years), 10 and 7 subjects were retained
for UCLA and LIJ, respectively. UCLA subjects received an
average of 10.7 ± 3.6 ECT treatments with most subjects
receiving right unilateral electrode placement and achieved an
improvement from a pre-ECT HDRS-17 of 25.5 ± 4.0 to a
post-ECT HDRS-17 of 10.8 ± 6.8 (po0.01, 20.0% remitters).
The lower remitter rates in the UCLA sample are related to
the more stringent remission criteria for the HDRS-17 (o7).
LIJ included 7 MDD subjects (age 62.0 ± 7.5 years, 5 males)
that received fewer ECT treatments, 7.3 ± 3.5, with bi-frontal
electrode placement. LIJ MDD subjects had a response from a
pre-ECT HDRS-24 of 30.7 ± 4.8 to a post-ECT 16.7 ± 11.8
(po0.01, 42.9% remitters).

Data Acquisition and Preprocessing
Structural magnetic resonance imaging data were collected at
UNM on a 3 Tesla Siemens Trio scanner (repetition
time = 2.53 s (s), echo time = 1.64, 3.50, 5.32, 7.22, 9.08 ms,
inversion time = 1.20 s, flip angle = 7, number of excitations = 1, and voxel size = 1 × 1 × 1 mm3), LIJ on a 3T GE
HDx scanner (Argyelan et al, 2016), and UCLA on a 3-T
Allegra scanner (Joshi et al, 2016). Using the unified
segmentation methods of SPM8, the sMRI data were
normalized to Montreal Neurologic Institute (MNI) space,
resliced to 3 × 3 × 3 mm3 and segmented into GM, white
matter and cerebral spinal fluid. The GM imaes were
smoothged with a full width at half maximum
8 × 8 × 8 mm3 Gaussian filter. Subject outlier detection was
performed with a spatial Pearson’s correlation with the MNI
template image, to ensure that all subjects were properly
segmented (Gupta et al, 2015) and no outliers were found.

Individualized Prediction
ECT Procedure
The UNM ECT service used a Thymatron System IV
(Somatics, Lake Bluff, IL, USA) and started with a right
unilateral d’Elia (ultra-brief pulse width (0.3 ms), stimulus
dosage at 6 × threshold) electrode placement unless bitemporal (brief pulse width (1 ms), stimulus dosage at 2 ×
threshold) electrode placement was clinically indicated.
UCLA used a Mecta 5000Q (MECTA Corp., Tualatin, OR,
USA) with similar electrode placement and stimulus dosages.
LIJ used Thymatron System IV with bifrontal electrode
placement (brief pulse width (1 ms), stimulus dosage at 1.5 ×
threshold). Further adjustments to energy occurred as
needed for inadequate seizure duration, defined as o25 s
of electroencephalogram seizure activity. Treatments occurred three times weekly until adequate clinical response or
clinical decision to stop treatment for non-responders. ECT
management was not manipulated for purposes of this
investigation and followed accepted clinical standards as
promulgated by the APA ECT Task Force Report. Patients
were oxygenated throughout the procedure with a disposable
bag and mask. Blood pressure, pulse and oxygen saturation
were monitored throughout the procedure.
Neuropsychopharmacology

We previously developed a generalized, data-driven prediction framework, which has successfully predicted cognitive
scores for individuals with a high accuracy, by whole-brain
voxel-wise searching on MRI data (Meng et al, 2017). Here
we adopted this algorithm to select baseline (pre-ECT)
structural imaging features to predict eventual change in
depression rating scores (ΔHDRS = pre-ECT HDRS − postECT HDRS) using UNM data set. Rigorous nested crossvalidation (10-fold and leave-one-out) was performed, to
ensure the validity of the detected GM features, as shown in
Supplementary Figure S1.
In the leave-one-out loop, one subject was left out as the
test subject, the remaining 37 subjects were used as training
set, which was repeated 38 times (equal to the subject length)
to test through all subjects. For the training subjects, we first
utilized a whole-brain, voxel-wise feature selection method
called ReliefF (Stokes and Visweswaran, 2012), to identify the
most relevant voxel features to the predicted measure
(ΔHDRS); see more method details in Supplementary File
S3. Then spatial clustering was performed on the above
selected voxels, to obtain a reduced number of GM ROI
clusters, which were further averaged to result in ROI-based
features. Compared with a fixed brain atlas, this data-driven
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clustering is more flexible and may increase the accuracy of
the prediction network as reported in Meng et al (2017).
Third, the cluster-based features were further refined by
correlation-based feature selection (Tripoliti et al, 2010),
producing an optimal feature subset that is highly correlated
with the predicted measure (ΔHDRS) but has low redundancy within itself. This step is necessary, as the derived
ROI-based features (GM regions) may indicate decreased
relevance to the target measure compared with initial voxelwise features and may contain redundant information.
Finally, a set of GM ROIs were combined in a 10-fold linear
regression analysis to predict the continuous value of
ΔHDRS. Here, both spatial clustering and correlationbased feature selection can be viewed as a feature reduction
strategy, with no parameters needed to be tuned in our
framework. At each loop, we calculated the predicted
ΔHDRS for each left-out subject and obtained the identified
GM ROIs, which can be common or different loop by loop.
After performing nested cross-validation, the unbiased
prediction of ΔHDRS for all the UNM subjects was achieved.
By selecting the GM regions that were most frequently
identified in all 38 loops (occurrence more than half of the
loop times, 38/2 = 19), we finally determined six GM ROIs as
a predictive network of the clinical target (ΔHDRS), as
shown in Figure 1a. Based on the predicted ΔHDRS and the
baseline HDRS, we can calculate the post-ECT HDRS for
each patient, who can be further classified as remitter or

non-remitter according to the clinical assessment (Heijnen
et al, 2010). Finally, compared with true treatment outcome,
the sensitivity, specificity, positive predictive value, negative
predictive value, and the prediction accuracy for remitter
were calculated; please see more details in the Supplementary
Methods Section.

Independent Cohort Validation of Identified GM
Regions
We further used two independent datasets (LIJ and UCLA),
to evaluate the validity of the identified GM ROIs for
predicting ECT treatment outcome. Namely, whether
individual symptom changes can be predicted solely based
on these identified ROIs in new data sets. Same ROI features
(as shown in Figure 1a) were extracted from UCLA and LIJ
data sets. Then we ran linear regression using a leave-oneout cross-validation for each site, in which the six GM ROIs
were used as regressors. The ΔHDRS for these two sites were
then estimated with site-specific β-weights and the dichotomous remitter criterion was further adopted to predict the
post-ECT treatment outcome. Owing to the heterogeneity of
age between UNM (50 ~ 80 years old) and UCLA/LIJ (20 ~ 74
years old), we separate the validation data set into different
age groups and applied the leave-one-out linear regression to
(1) entire validation subjects, (2) subjects with an age > 40
years, and (3) subjects with an age > 50 years, respectively. In

Figure 1 (a) The six identified pre-electroconvulsive therapy (ECT) gray matter (GM) regions of interest (ROIs) as predictors of ΔHDRS in sagittal and axial
view. The six extracted GM ROIs contributing to the prediction of ECT treatment outcome, include right hippocampus/ parahippocampus (Brodmann area
(BA) 30), right inferior temporal gyrus (ITG; BA 37), right middle frontal gyrus (MFG; BA 10, 11), left lingual gyrus (BA 19, 39), left postcentral gyrus/precuneus
(BA 1,2,3,7), and left supplementary motor area (SMA)/superior frontal gyrus (SFG) (BA 6). (b) Repeated-measures analysis of variance (RM-ANOVA)
identified GM changes before and after ECT in only two predicitve regions: the left postcentral gyrus/precuneus and left SMA/SFG. Post-hoc t-tests on these
regions demonstrated increased GM density for both regions with ECT. Relative to HCs, the left SMA/SFG had less GM density in major depressive disorder
(MDD) both at pre-ECT (pre-ECT/healthy control (HC) T(36) = 4.45, po0.001) and post-ECT (post-ECT/HC T(36) = 3.35, po0.001). (c) Four treatmentresponsive regions identified by voxel-wise RM-ANOVA with group × time interaction, including right insula, right superior temporal gyrus, parahippocampal
gyrus, and postcentral gyrus. (d) Longitudinal GM changes for six predictive ROIs and four treatment-responsive regions. The magnitude of longitudinal GM
change is much greater in treatment-responsive network than in treatment-predictive regions (po0.001). See more details in Supplementary Table S1.

Neuropsychopharmacology
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Figure 2 Scatter plot of the predicted ΔHDRS (pre–post) with respect to their true values for three sites. (a) A Spearman’s correlation of r = 0.91 was
achieved between the estimated ΔHDRS and its true values in University of New Mexico (UNM). For sub-group depressed patients with (blue dots) or
without (red dots) psychotic features, the Spearman’s correlations are 0.89 and 0.93, respectively (not listed in figure), indicating no significant differences
between two major depressive disorder (MDD) subgroups. Based on the estimated ΔHDRS and the pre- electroconvulsive therapy (ECT) Hamilton
Depression Rating Scale (HDRS), patients were further classified as remitter or non-remitter. By extracting the same six gray matter (GM) regions as identified
in UNM and using them as regressors for two independent cohorts: Long Island Jewish Health System (LIJ) and University of California at Los Angeles (UCLA),
we performed leave-one-out linear regression analyses. (b) Prediction accuracies in validation sites with different age ranges. In the two validation sites, the
derived classification accuracy for remission status range from 40% to ~ 65% for the entire validation sample and for subjects with age > 40 years. However,
when only include the age-matched subjects with UNM (ie, age > 50 years), we achieved Spearman correlation of r = 0.75 (c) and r = 0.74 (d) for LIJ and
UCLA, respectively. Furthermore, high prediction precision for remission status were also achieved (UCLA: sensitivity 100%, specificity 87.5%, and accuracy
90.0%; LIJ: sensitivity 66.7%, specificity 100%, and accuracy 95.7%).

addition, to demonstrate the validity of the selected 6
predictive GM ROIs, we also randomly selected 6 GM ROIs
from 116 atlas-based ROIs derived from AAL (Automated
Anatomical Labeling) atlas segmentation and performed the
same linear regression with leave-one-out cross-validation.
The process was repeated for 100 times in each of the two
validation data sets and the results were compared with what
we obtained using the 6 identified GM ROIs.

Longitudinal Analyses and Group Comparison
For the UNM data set, repeated-measures analysis of
variance (RM-ANOVA) assessed group (MDD and HC) ×
time interaction for GM density extracted from each of the
six GM regions. Post-hoc two-sample (pre-ECT/HC, postECT/HC), paired (pre-/post-ECT) t-tests, and correlations
between ΔHDRS and ΔGM were performed on the
Neuropsychopharmacology

identified predictive network to determine the directionality
of change for significant interactions. Paired two-sample ttests were also performed in each of the six GM regions (preand post-ECT) for MDD remitters and non-remitters to
detect the influence of ECT on GM densities. In addition,
group comparison among remitters, non-remitters, and HCs
at baseline and at the second timepoint were conducted with
two-sample t-tests. Finally, RM-ANOVA was used to assess
group (MDD and HC) × time interaction for the whole brain
voxel-wise GM density with FDR correction for multiple
comparisons.

RESULTS
Identified Predictive GM Regions
Six GM ROIs were identified as a set of predictors for ECT
treatment response in UNM data (Figure 1(a)): (1) right
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Table 2 Prediction Accuracy of ΔHDRS and ECT Remitters for Three Sites
UCLA > 50 years

UNM
No. of subjects

38

Correlation r/p

0.91/2e − 15

RMSE

10

True non-remitter

7

0.75/0.01

6.0

True remitter

LIJ > 50 years

0.74/0.05

5.8

7.0

Predicted remitter

Predicted non-remitter

Predicted remitter

Predicted non-remitter

Predicted remitter

24

3

2

0

2

Predicted non-remitter
1

1

10

1

7

0

4

Sensitivitya

88.9%

100%

66.7%

a

Specificity

90.9%

87.5%

100%

PPVa

96.0%

66.7%

100%

NPVa

76.9%

100%

80.0%

Accuracya

89.5%

90.0%

85.7%

Abbreviations: ECT, electroconvulsive therapy; HDRS, Hamilton Depression Rating Scale; LIJ, Long Island Jewish Health System; MDD major depressive disorder; NPV,
negative predictive value; PPV, positive predictive value; RMSE, root mean squared prediction error; UCLA, University of California at Los Angeles; UNM, University of
New Mexico.
a
Based on the predicted ΔHDRS and the pre-ECT HDRS, the post-ECT HDRS could be estimated and each MDD patient can further be classified as remitter or nonremitter according to (Heijnen et al, 2010). Here, sensitivity is defined as number of correctly predicted remitters divided by number of true remitters; specificity is
defined as number of correctly predicted non-remitters divided by number of true non-remitters; PPV is defined as number of correctly predicted remitters divided by
number of predicted remitters; NPV is defined as number of correctly predicted non-remitters divided by number of predicted remitters; accuracy is defined as number
of correctly predicted remitters and non-remitters divided by number of all MDD.

middle frontal gyrus (MFG; Brodmann area (BA) 10,11); (2)
right hippocampus and parahippocampus (BA 30); (3) right
ITG (BA 37); (4) left postcentral gyrus/precuneus (BA 1, 2, 3,
and 7); (5) left supplementary motor area (SMA) and
superior frontal gyrus (SFG) (BA 6); and (6) left lingual gyrus
(BA 39, 19).

Prediction Accuracy (UNM Cohort)
The predicted ΔHDRS from the UNM pre-ECT sMRI data
had a Spearman’s correlation of r = 0.91 with true ΔHDRS
(Figure 2a), root mean squared prediction error (RMSE) =
6.0. MDD subjects either with psychotic features (blue dots,
n = 16) or without psychotic features (red dots, n = 22) had
similar results (r = 0.89 and 0.93, respectively). In addition,
based on the predicted ΔHDRS, binary classification of
MDD patients as remitters/non-remitters achieved a high
degree of precision (sensitivity 88.9%, specificity 90.9%, and
accuracy 89.5%) (Table 2). Prediction of remission status
from these six ROIs with linear regression via leave-one-out
cross-validation also resulted in high precision (sensitivity
81.5%, specificity 90.9%, and 84.2% accuracy).

Independent Cohort Validation Using Six Identified GM
Regions
In the two validation sites, as shown in Figure 2b, the derived
classification accuracy for remission status ranged from 40%
to ~ 65% for the entire validation sample and for subjects
with age > 40 years. However, when including only agematched subjects with UNM (ie, age > 50 years), more
accurate results were obtained. For UCLA, 10 subjects were
retained and the six GM ROIs predicted ΔHDRS at
Spearman’s correlation of r = 0.75, RMSE = 5.8, with a
90.0% classification accuracy for remitters vs non-remitters
(sensitivity 100% and specificity 87.5%) and thus all remitters

were correctly predicted. For LIJ > 50 years (n = 7), ΔHDRS
prediction reached a Spearman’s correlation of r = 0.74
between true and predicted values, RMSE = 7.0, achieving a
remission classification at an accuracy of 85.7% (sensitivity
66.7% and specificity 100%), see Figure 2c and d, and
Table 2.
In contrast, predictions from six randomly selected AALbased ROIs achieved a mean correlation of r = 0.29 ± 0.21
and 0.31 ± 0.18 for LIJ and UCLA data set, respectively, for
all three age ranges, significantly lower than results derived
via the six identified GM ROIs (po0.0001). Consequently,
for the randomly selected ROIs, the remission classification
accuracy remained low in every permutation (accuracyo70% in all cases), further confirming the effectiveness
of the identified six GM ROIs for predicting treatment
outcome in a specific age range.

Longitudinal Analysis and Group Comparison
To examine longitudinal changes, RM-ANOVA was applied
to each of six predictive regions and we identified two
regions with group (MDD/HC)-by-time interactions for the
UNM data, ie, the left postcentral gyrus/precuneus ROI (F(3,
64) = 7.8, p = 0.007) and the left SMA/SFG ROI (F(3,
64) = 13.4, po0.001, see Figure 1(b), Supplementary Table
S1. Post-hoc t-tests on these regions demonstrated increased
GM density for both left postcentral gyrus/precuneus (T
(37) = 3.24, p = 0.003) as well as left SMA/SFG (T(37) = 3.68,
po0.001). Relative to HCs, the left SMA/SFG had less GM
density in MDD both for pre-ECT (T(36) = 4.45, po0.001)
and post-ECT (T(36) = 3.35, po0.001). However, none of
the six GM ROIs showed significant correlations between
changes of GM (ΔGM) and depression ratings (ΔHDRS).
Figure 1c indicated the voxel-wise RM-ANOVA results of
group × time interaction, four regions including right insula,
right superior temporal gyrus, parahippocampal gyrus, and
Neuropsychopharmacology
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Figure 3 Longitudinal gray matter (GM) changes among remitters, non-remitters, and healthy controls on the six identified GM regions. Subplot a-f denotes
each of the six regions, see title of the subplots. Longitudinal GM density increases were observed for remitters in all five of the six GM regions (the right
orbitofrontal gyrus did not demonstrate longitudinal change). None of these regions showed significant differences for non-remitters. Five of the six GM
regions had baseline (pre- electroconvulsive therapy (ECT)) GM density differences between remitters and non-remitters (po0.05) (the right hippocampus/
parahippocampus did not reveal pre-ECT remitter/non-remitter differences), suggesting structural heterogeneity exists between remitters and non-remitters.

postcentral gyrus were identified as treatment-responsive
network. Figure 1d demonstrated the longitudinal GM
changes for six predictive ROIs and four treatmentresponsive regions. Remarkably, the magnitude of longitudinal GM change is much greater in treatment-responsive
network than in treatment-predictive regions.
Figure 3 demonstrated GM changes before and after ECT
among three groups: MDD remitters, MDD non-remitters,
and HCs. Interestingly, longitudinal GM density increases
were observed for remitters in all five of the six GM regions
(right MFG did not demonstrate longitudinal change),
whereas none of these regions showed significant increases
or reduction for non-remitters. Five of the six GM regions
had baseline (pre-ECT) GM density differences between
remitters and non-remitters (po0.05) (right hippocampus/
parahippocampus region did not demonstrate this difference) with remitters and HC group demonstrating higher
(Figure 3f) or lower (only for ITG, Figure 3b) GM density
than non-remitters at baseline.
Neuropsychopharmacology

DISCUSSION
The goal of developing biomarkers for prognosis is to
perform individualized predictions of health outcome
(Gabrieli et al, 2015). In this work, we adopted pre-ECT
segmented GM to predict the treatment outcome based on a
generalized prediction framework, which has been used to
predict individual cognitive scores successfully. Six GM ROIs
were identified as predictors of eventual remission status
after ECT, achieving accuracy of 89, 90 and 86% for three
independent, age-matched data sets, respectively, significantly higher than using randomly selected six atlas-based
ROIs. Although prior investigations in mental disorders
typically use binary (categorical) classification, we achieved
quantitative estimation of post-ECT changes in depression
ratings for each individual patient, which are highly
correlated with true ΔHDRS (r > 0.74 in three sites,
RMSEo7.0), and are robust to the presence of psychosis in
MDD. More importantly, effectiveness of the identified six
GM predictors was verified on two independent datasets, in
which relatively higher sensitivity and specificity was

Predicting ECT outcomes with sMRI data
R Jiang et al

1085

achieved on prediction of ECT remission status, especially
when compared with results from randomly selected six
AAL-based ROIs. Results suggest that individual depressive
symptom changes can be predicted solely based on the six
regions identified from the unbiased prediction framework,
and may serve as ECT treatment predictors specifically for
MDD patients who are older than 50 years.
A unique aspect of our work is that instead of focusing on
priori presumed regions, we employed whole-brain voxelwise data mining, followed by spatial clustering and feature
refining. Compared with an atlas-based feature selection and
alternative LASSO (least absolute shrinkage and selection
operator) method (Bunea et al, 2011), our technique enables
more flexibility and higher precision as reported in Meng
et al (2017) (see Supplementary Method Section), acquiring a
set of treatment-predictive GM regions which cannot be
identified by simple longitudinal analysis. In addition,
previous studies deriving predictive brain regions at one site
may not work well for other data sets (Wachinger et al,
2016). This may be related to over-fitting of the training data
at one site, especially when the training samples are limited,
while features are high dimensional. In the current
investigation, we used the source data (UNM) to identify a
predictive network (six ROIs) of depression rating changes,
which were further adopted as regressors in two independent
test sets (UCLA and LIJ) with a leave-one-out crossvalidation and achieved a significantly higher prediction
accuracy than using randomly selected six atlas-based ROIs.
This enables more flexibility to derive site-specific weights on
the fixed GM predictors. We can also incorporate sitespecific weights for each regression lines, representing a type
of transfer learning, similar to a recent transfer learning
method called domain adaptation (Wachinger et al, 2016),
which may serve as a future research direction. Finally, other
types of neuroimaging (functional MRI and diffusion
weighted imaging) and genomics can be employed for
prediction either separately or in the context of multimodal
fusion (Sui et al, 2014), which may detect potentially
important variations or relationships that may only be
partially revealed by single modality (Calhoun and Sui,
2016). A long-term goal of this line of research is to develop
tools that can facilitate clinical judgement.
Previous machine-learning ECT studies have investigated
imaging predictors of response (Redlich et al, 2016; van
Waarde et al, 2015; Wade et al, 2016). These investigations
have used resting state fMRI or structural measures from one
single data set. Similar to the current investigation, Redlich
et al (2016) applied classification using support vector
machines to pre-ECT sMRI data. The results demonstrated
that the subcallosal cingulate gyrus was a key region for ECT
response prediction with 84% accuracy, although other sMRI
regions also contributed. We identified six GM regions in
total, referred to as a ‘predictive network,’ which included
both cortical and subcortical regions that may predict
eventual clinical response with higher accuracy. Our
prediction network did not include the subcallosal cingulate
gyrus, perhaps due to different age ranges (the current
investigation included an older age range). However, our
identified GM ROIs did overlap with a previous report
(Costafreda et al, 2009), in which increased GM density in
MFG of MDD was predictive of eventual response to
pharmacotherapy (fluoxetine) (Costafreda et al, 2009).

In addition, the UNM predictive network failed to
maintain the response accuracy outside of the demographically matched external validation samples from UCLA and
LIJ. Age-related differences in response rates have been a
focus of clinical ECT prediction studies with older age (>50
years) often associated with more favorable ECT response
rates (Nordenskjold et al, 2012). Although not completed in
the present investigation, demographic, and clinical variables
(duration of depressive episode, number of depressive
episodes, age of depression onset, etc.) may be incorporated
into predictive imaging algorithms to improve response
accuracy. Alternatively, predictive networks may be identified for specific demographic categories (ie, predictive
network for age range 20–40 years) or depression phenotypes. Consistent with the latter, Drysdale et al (2017) used
hierarchical clustering analysis to identify depression biotypes from baseline neuroimaging data. Anxiety- and
anhedonia-related depression biotypes improved prediction
accuracy for transcranial magnetic stimulation for depressive
episodes.
Analysis demonstrated longitudinal GM changes in two of
the six identified ROIs: the left SMA/SFG and left post
central gyrus/precuneus. The locations of neuroplasticity
change are proximal to the site of maximal current density
for subjects that received right unilateral electrode placement. Interestingly, the remaining four identified GM
regions of the prediction network did not demonstrate any
significant change in GM density. The lack of longitudinal
change in predictive ROIs is consistent with a previous datadriven ECT investigation. Wade et al (2016) used baseline
GM volume and surface-based shape metrics of the caudate,
putamen, pallidum, and nucleus accumbens to predict
overall MDD response to ECT with up to 89% accuracy,
whereas only the left putamen volume showed significant
increase after ECT.
In contrast to the modest longitudinal GM density changes
in predictive biomarkers, whole brain longitudinal analysis
revealed changes in right medial temporal lobe neuroplasticity. Medial temporal lobe neuroplasticity, particularly of
the hippocampus, is now a widely replicated finding in the
ECT neuroimaging literature (Wilkinson et al, 2017). The
treatment-responsive region had little overlap with the six
predictive ROIs and more robust (order of magnitude)
increase in GM density relative to longitudinal changes with
the predictive ROIs. Similarly, Redlich et al (2016) used
longitudinal analysis to demonstrate similar changes in
medial temporal lobe neuroplasticty, which were separate
from their predictive biomarkers within the subcallosal
cingulate gyrus. Collectively, these results suggest that
predictive and treatment-responsive regions may be anatomically separate but functionally related in the context of
ECT response. Clarification of the relationship between
predictive and treatment-responsive biomarkers will inform
novel (and more focal) electrode placement development to
improve clinical outcomes (improved efficacy, reduced
cognitive impairment). fMRI effective connectivity analysis
may elucidate the relationship between predictive and
treatment-responsive biomarkers and further inform the
optimal biomarker(s) for targeted engagement.
Despite a high prediction accuracy and verification of the
use of potential biomarkers, limitations of this study should
be acknowledged when interpreting our results. First, UNM
Neuropsychopharmacology
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subjects were treated with antidepressant medications during
the baseline (pre-ECT) scan and throughout the ECT series.
Both UCLA and LIJ tapered and discontinued antidepressant
medications before the baseline assessment. Concurrent
treatment with some antidepressants may work synergistically with ECT (Sackeim et al, 2009) and share a similar but
less potent mechanism of action (Malberg et al, 2000).
However, our identified predictive ROIs were robust to these
clinical differences as well as other site-specific difference
such as electrode placement, scanner inhomogeneity, number of treatments, and the inclusion or exclusion of psychotic
subjects. Second, important clinical characteristics such as
age of onset and duration of depressive episode were not
assessed during this investigation and remain a focus of
subsequent investigations. Another potential limitation is
that the GM images were resliced to a voxel size of 3 × 3 × 3
and smoothed by an 8 × 8 × 8 kernel, which may tend to
render the results as more conservative.
To the best of our knowledge, this is the first attempt to
quantitatively identify and validate ECT treatment biomarkers based on multi-site pre-ECT sMRI data for individual
MDD patients, which could potentially discover a set of new
imaging features critical in treatment remission, and thus
guide personalized clinical care. Future applications of
machine learning may inform treatment-specific variables
such as electrode placement or optimal current amplitude.
Importantly, this same method may be applied to ECT
relapse too, which lacks any clinical or demographic
biomarker to guide clinical practice. Moreover, this investigation addressed a major clinical challenge and our identified
predictive regions may have broad impact on translational
medicine, by providing opportunities for more effective and
timely interventions. In sum, the methods developed in this
and other investigations on ECT prediction may be generalized to other depressed samples and different clinical
populations, further informing the precision medicine
initiative (Shah et al, 2016).
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